Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BRLIZIO
- Development stage
- Phase 3
- Lead developer
- Lipocine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BRLIZIO (LPCN 1154) is an investigational oral formulation of brexanolone, a neuroactive steroid chemically identical to endogenous allopregnanolone. It acts as a positive allosteric modulator of synaptic and extrasynaptic GABA-A receptors. Developed by Lipocine, BRLIZIO is designed as a short, 48-hour oral regimen for the rapid treatment of postpartum depression (PPD) in an outpatient or at-home setting, bypassing the need for the intensive healthcare monitoring required by intravenous formulations of brexanolone.
- Brand names
- BRLIZIO
- Other names
- oral brexanolone
02
Targets
GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on BRLIZIO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BRLIZIO.